Madrigal Pharmaceuticals reports positive financial results and appoints new leadership, presenting promising clinical trial data.
From GlobeNewswire: 2025-05-01 07:00:00
Madrigal Pharmaceuticals reported first-quarter 2025 Rezdiffra net sales of $137.3 million, with over 17,000 patients on the medication as of March 31. Two-year F4c data from the MAESTRO-NAFLD-1 trial will be presented at the EASL Congress. Key appointments were made to the company’s leadership team and board of directors. The company reported cash and marketable securities of $848.1 million as of March 31, 2025. A conference call will be held on May 1, 2025, at 8 a.m. EDT.
Rezdiffra, the first FDA-approved treatment for MASH, has shown positive results with improvements in liver health markers. The company aims to establish Rezdiffra as a foundational therapy for MASH treatment across different stages. Data from the MAESTRO-NAFLD-1 trial show promising results in reducing liver stiffness. The company will present at the EASL Congress and is awaiting regulatory decisions in Europe.
Madrigal Pharmaceuticals appointed a new Chief Medical Officer and Senior Scientific and Medical Advisor. Jacqueline Fouse, Ph.D., was appointed to the Board of Directors. Financially, the company reported total revenues of $137.3 million for the first quarter of 2025 and had cash and marketable securities totaling $848.1 million as of March 31, 2025. Operating expenses, including R&D and SG&A, increased compared to the previous year.
The company will host a conference call and webcast on May 1, 2025, to discuss financial results and corporate updates. Rezdiffra is a prescribed medicine for adults with NASH and has shown positive outcomes in clinical trials. The medication targets liver scarring and fibrosis. Patients should consult their healthcare provider before taking Rezdiffra, especially if they have other medical conditions or take specific medications. Reported side effects include liver injury and gallbladder problems.
Madrigal Pharmaceuticals focuses on delivering therapeutics for MASH, a liver disease with unmet medical needs. Rezdiffra is the first FDA-approved treatment for MASH with moderate to advanced fibrosis. The company is conducting ongoing trials to evaluate the medication’s effectiveness. Forward-looking statements address potential risks and uncertainties related to regulatory approvals, clinical trials, and market acceptance.
Financially, Madrigal Pharmaceuticals reported a net loss for the first quarter of 2025, with operating expenses and interest income and expenses detailed in the financial statements. The company’s balance sheet shows cash, cash equivalents, restricted cash, and marketable securities totaling $848.1 million as of March 31, 2025. The company’s liabilities and stockholder equity are also outlined in the financial statements.
Read more at GlobeNewswire:: Madrigal Pharmaceuticals Reports First-Quarter 2025